Kevin Bitterman, PhD

Kevin Bitterman focuses on creating and investing in companies that translate groundbreaking science into innovative medicines.

Kevin serves on the boards of Akero Therapeutics and Navitor Pharmaceuticals. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). He previously served as a director of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Taris Biomedical (acquired by Allergan) and Vets First Choice among other ventures. Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004.

Kevin is active in the local life science and healthcare start-up community, serving on the Scientific Advisory Board of the Massachusetts Life Sciences Center (MLSC) and as Board Chair of the New England Venture Capital Association (NEVCA).  He received a BA in biology, summa cum laude, from Rutgers University before completing his PhD in genetics at Harvard Medical School.